XBIO Relative Valuation
XBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XBIO is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for XBIO's competitors is 0.74, providing a benchmark for relative valuation. Xenetic Biosciences Inc Corp (XBIO) exhibits a P/S ratio of 1.67, which is 125.32% above the industry average. Given its robust revenue growth of 16.14%, this premium appears unsustainable.
People Also Watch
NVDA
NVIDIA Corp
135.570
USD
+0.13%
TSLA
Tesla Inc
342.090
USD
-2.25%
AVGO
Broadcom Inc
230.630
USD
+0.88%
AMZN
Amazon.com Inc
206.160
USD
+0.28%
WMT
Walmart Inc
98.120
USD
-0.12%
MSFT
Microsoft Corp
458.870
USD
+1.01%
XOM
Exxon Mobil Corp
106.470
USD
-1.59%
AAPL
Apple Inc
208.780
USD
-1.17%
ORCL
Oracle Corp
159.640
USD
-0.53%
META
Meta Platforms Inc
640.430
USD
+0.01%
FAQ
Is Xenetic Biosciences Inc (XBIO) currently overvalued or undervalued?
Xenetic Biosciences Inc (XBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.67 is considered Fairly compared with the five-year average of 9.95. The fair price of Xenetic Biosciences Inc (XBIO) is between 0.39 to 28.01 according to relative valuation methord.
What is Xenetic Biosciences Inc (XBIO) fair value?
How does XBIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Xenetic Biosciences Inc (XBIO) as of May 20 2025?
What is the current FCF Yield for Xenetic Biosciences Inc (XBIO) as of May 20 2025?
What is the current Forward P/E ratio for Xenetic Biosciences Inc (XBIO) as of May 20 2025?